Compare · CBLL vs SLNO
CBLL vs SLNO
Side-by-side comparison of CeriBell Inc. (CBLL) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.76B, about 3.0x CBLL ($919.2M).
- CBLL has been more active in the news (17 items in the past 4 weeks vs 1 for SLNO).
- SLNO has more recent analyst coverage (12 ratings vs 8 for CBLL).
- Company
- CeriBell Inc.
- Soleno Therapeutics Inc.
- Price
- -
- -
- Market cap
- $919.2M
- $2.76B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2014
- News (4w)
- 17
- 1
- Recent ratings
- 8
- 12
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest CBLL
- Chief Revenue Officer Manni Joseph S. sold $32,691 worth of shares (1,361 units at $24.02), decreasing direct ownership by 2% to 55,956 units (SEC Form 4) (tax liability)
- Senior VP, Finance and PAO Foehr David sold $44,425 worth of shares (1,852 units at $23.99) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 35,899 units (SEC Form 4) to cover withholding tax
- Chief Technology Officer Woo Raymond sold $47,536 worth of shares (1,979 units at $24.02), decreasing direct ownership by 1% to 194,729 units (SEC Form 4) (for tax liability)
- Chief Financial Officer Blumberg Scott sold $36,534 worth of shares (1,521 units at $24.02), decreasing direct ownership by 1% to 146,600 units (SEC Form 4) (tax liability)
- President and CEO Chao Xingjuan sold $145,753 worth of shares (6,068 units at $24.02), decreasing direct ownership by 0.77% to 781,731 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Blumberg Scott exercised 34,502 shares at a strike of $8.47 and sold $863,555 worth of shares (34,502 units at $25.03) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form 4 filed by Chief Financial Officer Blumberg Scott
- President and CEO Chao Xingjuan sold $841,292 worth of shares (33,614 units at $25.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 787,799 units (SEC Form 4)
- President and CEO Chao Xingjuan exercised 33,096 shares at a strike of $3.31, increasing direct ownership by 4% to 821,413 units (SEC Form 4)
- Director Taylor Joseph Michael sold $306,423 worth of shares (13,095 units at $23.40), decreasing direct ownership by 21% to 48,478 units (SEC Form 4)
Latest SLNO
- Amendment: SEC Form SCHEDULE 13G/A filed by Soleno Therapeutics Inc.
- Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
- SEC Form 15-12G filed by Soleno Therapeutics Inc.
- SEC Form EFFECT filed by Soleno Therapeutics Inc.
- SEC Form POS AM filed by Soleno Therapeutics Inc.
- SEC Form AW filed by Soleno Therapeutics Inc.
- Officer Yen Kristen returned 37,639 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Volck Birgitte returned 17,536 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sinclair Andrew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Pauls Matthew returned 10,491 shares to the company, closing all direct ownership in the company (SEC Form 4)